We are not changing our fair values to COVID-19 vaccine firms following the proposed waiver on intellectual property protection.

Covid will create a $52bn vaccine and treatment market and usher in immunity by 2023, writes Morningstar's Karen Andersen.

Resurgences in outbreaks make it clear that ending the pandemic requires more than testing, contact tracing, and social distancing, says...

We expect most US adults will be vaccinated in the first half of 2021, writes Morningstar healthcare strategist Karen Andersen.

Three new vaccines for coronavirus look poised for emergency use authorisation in the US this autumn. What does that mean for investors?

Diagnostic testing, treatment, and a coronavirus vaccine could allow near-normal distancing and nonessential business recovery by mid-2021.

Morningstar weighs supply and demand factors in assessing COVID-19's long-term effect on global GDP as minimal.

A forecast low fatality rate implies an overstated threat to the economy, says Morningstar's Karen Andersen.

A new book offers straightforward advice from start to finish.